CU22420A1 - Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer - Google Patents

Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer

Info

Publication number
CU22420A1
CU22420A1 CU92131A CU1993131A CU22420A1 CU 22420 A1 CU22420 A1 CU 22420A1 CU 92131 A CU92131 A CU 92131A CU 1993131 A CU1993131 A CU 1993131A CU 22420 A1 CU22420 A1 CU 22420A1
Authority
CU
Cuba
Prior art keywords
vaccine composition
present
acm
glycolylated
cancer
Prior art date
Application number
CU92131A
Other languages
English (en)
Inventor
Molina Luis Enrique Fernandez
Hernandez Oscar Gonzalo Valiente
Rodriguez Gilda Marquina
Perez Adriana Carr
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU92131A priority Critical patent/CU22420A1/es
Priority to EP94203736A priority patent/EP0661061B1/en
Priority to DE69428969T priority patent/DE69428969T2/de
Priority to ES94203736T priority patent/ES2168287T3/es
Priority to CA002139217A priority patent/CA2139217C/en
Priority to JP6328669A priority patent/JP3044173B2/ja
Priority to CN94113506A priority patent/CN1099894C/zh
Priority to US08/365,684 priority patent/US5788985A/en
Publication of CU22420A1 publication Critical patent/CU22420A1/es
Priority to US09/061,710 priority patent/US6149921A/en
Priority to CN01144023A priority patent/CN1371690A/zh
Priority to HK03101194.9A priority patent/HK1048942A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON LA RAMA DE LA INMUNOTERAPIA ACTIVA E DE LA PRODUCCION INDUSTRIAL DE ACM. EN PARTICULAR, EL NGCGM3, UN ANTIGENO PRESENTE EN LOS TUMORES DE MAMA, PUEDE OBTENERSE DE ESTE MODO: ESTE GANGLIOSIDO Y/O UN DERIVADO DE ESTE Y/O SU CORRESPONDIENTE OLIGOSACARIDO, ACOPLADOS MEDIANTE ENLACES HIDROFOBOS O COVALENTES A VEHICULOS APROPIADOS; ESTA COMPOSICION VACUNAL ADEMAS CONTIENE UN ADYUVANTE, QUE PUEDE SER DE ORIGEN NATURAL O ACM. EL CAMPO DE LA PRESENTE INVENCION ES EL DE LA TERAPEUTICA DEL CANCER, PARTICULARMENTE DEL CANCER DE MAMA, MEDIANTE EL EMPLEO DE VACUNAS. ESPECIFICA DEL CANCER Y ENTRE OTRAS PROPORCIONA UNA COMPOSICION VACUNAL PARA LA GENERACION O EL INCREMENTO DE LA RESPUESTA INMUNE DE ANTICUERPOS CONTRA GANGLIOSIDOS N GLICOLILADOS. EL OBJETO DE ESTA INVENCION ES PROPORCIONAR UNA COMPOSICION VACUNAL PARA LA PREVENCION Y EL TRATAMIENTO DEL CANCER QUE CONTIENE UNA CANTIDAD EFECTIVA DE UN GANGLIOSIDO N- GLICOLILADO PURO, PRINCIPALMENTE NGCGM3 Y/O MEDIANTE ENLACES HIDROFOBOS O COVALENTES A VEHICULOS APROPIADOS; ESTA COMPOSICION VACUNAL ADEMAS CONTIENE UN ADYUVANTE, QUE PUEDE SER DE ORIGEN NATURAL O ANTICUERPOS MONOCLONALES (ACM). OTRO OBJETIVO DE LA PRESENTE INVENCION CONSISTE EN USAR COMO FUENTE NATURAL ESCALABLE DE LOS GANGLIOSIDOS N - GLICOLILADOS LA BIOMASA DE HIBRIDOMAS RESULTANTE DE LA PRODUCCION INDUSTRIAL DE ANTICUERPOS MONOCLONALES. UN ASPECTO DE ESTA INVENCION CONSISTE EN OBTENER GANGLIOSIDOS N- GLICOLILADOS A PARTIR DE LA BIOMASA DE HIBRIDOMAS RESULTANT\!
CU92131A 1993-12-29 1993-12-29 Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer CU22420A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU92131A CU22420A1 (es) 1993-12-29 1993-12-29 Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
EP94203736A EP0661061B1 (en) 1993-12-29 1994-12-22 Vaccine composition for eliciting an immune response against N-glycolylated gangliosides and its use for cancer treatment
DE69428969T DE69428969T2 (de) 1993-12-29 1994-12-22 Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel
ES94203736T ES2168287T3 (es) 1993-12-29 1994-12-22 Vacuna capaz de provocar una respuesta inmunitaria contra los gangliosidos n-glicolados y su aplicacion anti-cancerosa.
JP6328669A JP3044173B2 (ja) 1993-12-29 1994-12-28 Ｎ−グリコリル化ガングリオシドに対する免疫応答を誘発させるワクチン組成物および癌処置におけるその使用
CA002139217A CA2139217C (en) 1993-12-29 1994-12-28 Vaccine composition for eliciting an immune response against n-glycolylated gangliosides and its use for cancer treatment
CN94113506A CN1099894C (zh) 1993-12-29 1994-12-28 引发抗ｎ－羟乙酰化神经节苷脂免疫反应的疫苗组合物及其应用
US08/365,684 US5788985A (en) 1993-12-29 1994-12-29 Vaccine composition for eliciting an immune response against N-glycolylated gangliosides and its use for cancer treatment
US09/061,710 US6149921A (en) 1993-12-29 1998-04-17 Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CN01144023A CN1371690A (zh) 1993-12-29 2001-12-25 引发抗n－羟乙酰化神经节苷脂免疫反应的疫苗组合物及其应用
HK03101194.9A HK1048942A1 (zh) 1993-12-29 2003-02-18 引发抗n-羟乙酰化神经节苷脂免疫反应的疫苗组合物及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU92131A CU22420A1 (es) 1993-12-29 1993-12-29 Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer

Publications (1)

Publication Number Publication Date
CU22420A1 true CU22420A1 (es) 1996-01-31

Family

ID=45992881

Family Applications (1)

Application Number Title Priority Date Filing Date
CU92131A CU22420A1 (es) 1993-12-29 1993-12-29 Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer

Country Status (9)

Country Link
US (1) US5788985A (es)
EP (1) EP0661061B1 (es)
JP (1) JP3044173B2 (es)
CN (2) CN1099894C (es)
CA (1) CA2139217C (es)
CU (1) CU22420A1 (es)
DE (1) DE69428969T2 (es)
ES (1) ES2168287T3 (es)
HK (1) HK1048942A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
WO2001081371A1 (en) 2000-04-25 2001-11-01 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetic peptides
PE20020572A1 (es) 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
CA2772876C (en) 2009-09-01 2019-01-15 Lz Therapeutics, Inc. Methods for extraction and purification of gangliosides
WO2011146804A2 (en) * 2010-05-20 2011-11-24 Lazarus Therapeutics, Inc. Gm3 ganglioside replacement therapy
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
JPH01500119A (ja) * 1986-05-07 1989-01-19 スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ Ｇｍ２に対する抗体の産生を賦活又は増強させるためのワクチン
NZ222192A (en) * 1986-10-20 1991-03-26 Kanto Ishi Pharma Co Ltd Glycolipid containing n-glycolylneuraminic acid, and preparation thereof
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
CA2057010C (en) * 1989-05-25 2002-08-06 Paul B. Chapman Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
CA2101648C (en) * 1991-03-12 2003-09-09 Rachel Schneerson Polysaccharide-protein conjugates
ATE188874T1 (de) * 1992-08-18 2000-02-15 Centro Inmunologia Molecular Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen
NZ314058A (en) * 1993-01-22 2000-08-25 Sloan Kettering Inst Cancer Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer

Also Published As

Publication number Publication date
CN1099894C (zh) 2003-01-29
JP3044173B2 (ja) 2000-05-22
DE69428969T2 (de) 2002-08-22
CA2139217A1 (en) 1995-06-30
HK1048942A1 (zh) 2003-04-25
ES2168287T3 (es) 2002-06-16
JPH0853366A (ja) 1996-02-27
DE69428969D1 (de) 2001-12-13
CN1371690A (zh) 2002-10-02
EP0661061A2 (en) 1995-07-05
CA2139217C (en) 2001-08-07
CN1122247A (zh) 1996-05-15
US5788985A (en) 1998-08-04
EP0661061B1 (en) 2001-11-07
EP0661061A3 (en) 1996-12-04

Similar Documents

Publication Publication Date Title
CU22420A1 (es) Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.
ES8700298A1 (es) Un procedimiento para la preparacion de conjugados estables y covalentemente copulados de polisacarido-proteina.
MX9306924A (es) Composiciones antitumorales que contienen derivados de taxano.
MX9705349A (es) Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas.
UY24354A1 (es) Composiciones farmacéuticas que contienen epinastina
ES2134761T3 (es) Nuevos compuestos bifuncionales enlazantes, conjugados y procedimientos para su produccion.
ES2070269T3 (es) Peptidos sinteticos utiles como portadores universales para la preparacion de conjugados inmunogenicos y su empleo en el desarrollo de vacunas sinteticas.
DK0550477T3 (da) Inaktiveret Mycoplasma hyopneumoniae-bakterin og fremgangsmåde til anvendelse deraf
UY28289A1 (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores
PE20211473A1 (es) Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
CO2023016246A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos
AR052541A1 (es) Vacunas de glicoconjugados que contiene peptidoglicina
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
CR5812A (es) Induccion de esterilidad masculina en plantas mediante expresion de elevados niveles de adivina
ES2166770T3 (es) Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
ES2183815T3 (es) Quimioterapia para el cancer.
ES2149759T3 (es) Vacuna contra la enfermedad de lyme.
DK0525119T3 (da) Antistofkonjugater til behandling af neoplastisk sygdom
WO2020146434A3 (en) Ex vivo activated t-lymphocytic compositions and methods of using the same
ES2152016T3 (es) Solucion oftalmica de pranoprofeno conteniendo amina organica.
ES2054643T3 (es) Un procedimiento para la despolimerizacion controlada de polisacaridos.
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso
PE72699A1 (es) Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno
ES2185671T3 (es) Depsipeptidos ciclicos que contienen acido lactico con 18 atomos en el anillo como agentes endoparasticidas y procedimiento para su obtencion.